Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure
A Phase I/II Study to Evaluate the Safety and Tolerability of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure
Sponsor: Elixirgen Therapeutics, Inc.
Listed as NCT04211714, this PHASE1 trial focuses on Bone Marrow Failure and Telomere Shortening and remains ongoing. Sponsored by Elixirgen Therapeutics, Inc., it has been updated 12 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Oct 2025 — Feb 2026 [monthly]
Recruiting PHASE1
-
Dec 2024 — Oct 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
▶ Show 7 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Jun 2023 — Jul 2024 [monthly]
Recruiting PHASE1
-
May 2022 — Jun 2023 [monthly]
Recruiting PHASE1
-
May 2021 — May 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE1
-
Jul 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Elixirgen Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .